Buy PHIO by Nov 17, 2026.

​ Longtime lurker. After watching $MRNA go absolutely nuclear on its Phase 3 cancer-vaccine data, I started looking farther down the oncology pipeline. PHIO is sitting near $1 with a tiny valuation while developing an RNAi cancer immunotherapy. The interesting part: early Phase 1 data from PH-762 has reported complete responses in treated tumors in some patients. Obviously Phase 1 ≠ Phase 3, tiny sample sizes matter, and this could still completely fail. But that's exactly why the valuation is …